Massachusetts Financial Services’s Blueprint Medicines BPMC Stock Holding History

Massachusetts Financial Services’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-60,349	Closed	-$7.74M	–	867
2025 Q2	$7.74M	Sell	60,349 -210,647	-78%	-$21.9M	﹤0.01%	693
2025 Q1	$24M	Buy	270,996 +1,006	+0.4%	+$98.1K	0.01%	576
2024 Q4	$23.5M	Buy	269,990 +17,754	+7%	+$1.63M	0.01%	584
2024 Q3	$23.3M	Buy	252,236 +82,693	+49%	+$8.21M	0.01%	578
2024 Q2	$18.3M	Buy	+169,543	New	+$17M	0.01%	586

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Massachusetts Financial Services's BPMC Position: Q3 2025 in Review

Massachusetts Financial Services sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 60,349 shares — an estimated $7.74M sold.

Massachusetts Financial Services first reported a position in BPMC in Q2 2024 and held it in 5 quarters. The position peaked at $24M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Massachusetts Financial Services reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Massachusetts Financial Services sold 60,349 Blueprint Medicines shares in Q3 2025, an estimated $7.74M.
Massachusetts Financial Services first reported a position in Blueprint Medicines in Q2 2024 and held it in 5 quarters.
Massachusetts Financial Services's Blueprint Medicines position peaked at $24M in Q1 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Massachusetts Financial Services's 13F filing for Q3 2025, filed 29 Oct 2025.